Pharmafile Logo

compulsory licence

- PMLiVE

Building BRICs: pharma’s key emerging markets are becoming giants

The BRIC nations – Brazil, Russia, India and China – for so long the leading lights of the emerging markets movement, may soon need to relinquish their 'emerging' tag and...

- PMLiVE

Pay-for-delay deals lead to inflated drug prices says study

Based on analysis of delayed market entry of generic Adderall XR in US

- PMLiVE

J&J acquires oncology candidate in $1bn Aragon buy

ARN-509 is in phase II development for castration resistant prostate cancer

- PMLiVE

Men’s oesophageal cancer risk “triple that of women”

New data from Cancer Research UK shines slight on 'quiet epidemic'

- PMLiVE

Elotuzumab on track for multiple myeloma

BMS and AbbVie present phase II results at European Haematology Association meeting

- PMLiVE

BMS partners with Simcere to market arthritis drug Orencia SC in China

Builds on existing cancer/ cholesterol alliance between pharma companies

- PMLiVE

Roche’s Avastin gains Japanese approval for brain cancer

Marks drug's first approval to treat newly diagnosed glioblastoma

Teva and Sun pay dearly for ‘at-risk’ generic Protonix launch

Will pay $2.15bn in landmark patent infringement lawsuit

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

Roche - Basel

EU approves new use of Roche’s RoActemra in children

Swiss pharma firm hopes to increase revenue from arthritis drug to tip it into blockbuster status

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

JWT Brazil devises superhero theme for paediatric oncology patients

Agency draws on Warner Bros characterisation to make treatment more child-friendly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links